http://www.onclive.com/onclive-tv/dr-roboz-on-impact-of-ctl019-in-all
Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

Gail J. Roboz, MD



Gail J. Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019; Kymriah) in select pediatric and young adult patients with a form of acute lymphoblastic leukemia (ALL).
Printer Printing...